Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

Y0000341

Loperamide oxide monohydrate

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

trans-4-(4-Chlorophenyl)-4-hydroxy-N,N-dimethyl-α,α-diphenyl-1-piperidinebutanamide 1-oxide monohydrate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C29H33ClN2O3 · H2O
Número de CAS:
106900-12-3
Peso molecular:
511.05
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

loperamide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C29H33ClN2O3/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32(35)20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3

InChI key

KXVSBTJVTUVNPM-UHFFFAOYSA-N

Categorías relacionadas

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Loperamide oxide monohydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Related product

Referencia del producto
Descripción
Precios

1370000

Loperamide hydrochloride, United States Pharmacopeia (USP) Reference Standard

PHR1162

Loperamide hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

L0750000

Loperamide hydrochloride, European Pharmacopoeia (EP) Reference Standard

1370065

Loperamide Related Compound F, United States Pharmacopeia (USP) Reference Standard

BP635

Loperamide hydrochloride, British Pharmacopoeia (BP) Reference Standard

BP636

Loperamide N-oxide, British Pharmacopoeia (BP) Reference Standard

1370010

Loperamide System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

Y0002087

Loperamide for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR9195

4-(4-Chlorophenyl)-4-hydroxypiperidine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR2916

Loperamide Related Compound F, pharmaceutical secondary standard, certified reference material

Pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

G Stacher et al.
Digestive diseases and sciences, 37(2), 198-204 (1992-02-01)
This crossover, double-blind study investigated the effects of single oral doses of the prodrug loperamide oxide, which is reduced gradually to loperamide in the intestine, and loperamide on jejunal motor activity in 12 fasting healthy men. Five minutes after a
M Göke et al.
Diseases of the colon and rectum, 35(9), 857-861 (1992-09-01)
The objective of this study was to investigate the effects of the opioid loperamide and its recently synthesized pharmacologically inactive prodrug loperamide oxide on the anal sphincter. In a double-blind, placebo-controlled crossover study, anorectal manometry was performed in 12 healthy
E Beubler et al.
The Journal of pharmacy and pharmacology, 45(9), 803-806 (1993-09-01)
In-vivo experiments in the rat jejunum have been performed to compare the antisecretory effect of orally administered loperamide with the effect of its pro-drug, loperamide oxide. Both loperamide and loperamide oxide, administered orally, reduced the secretory effect of prostaglandin E2
E Beubler et al.
The Journal of pharmacy and pharmacology, 42(10), 689-692 (1990-10-01)
The antidiarrhoeal effect of loperamide is caused by its antimotility and antisecretory properties. In-vivo experiments in the rat jejunum and colon have been performed to compare the antisecretory effect of loperamide with the effect of its prodrug, loperamide oxide. Both
J Hardcastle et al.
The Journal of pharmacy and pharmacology, 45(10), 919-921 (1993-10-01)
Mucosal loperamide inhibited the absorption of glycine by everted sacs of rat small intestine over 10-, 30- or 60-min incubation periods, but loperamide oxide was without effect. In stripped intestinal sheets, loperamide inhibited the rise in short-circuit current associated with
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico